Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
28 hedge funds and large institutions have $63M invested in Alpine Immune Sciences Inc in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
4% more funds holding
Funds holding: 27 → 28 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
29% less capital invested
Capital invested by funds: $88.9M → $63M (-$25.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$334K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$269K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$205K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$201K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
+$101K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.68M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$134K |
| 3 |
Millennium Management
New York
|
-$45.1K |
| 4 |
SIM
Spark Investment Management
New York
|
-$29.6K |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $1K | -$7.8K | -789 | -89% |
|
|
PWM
27
Perigon Wealth Management
San Francisco,
California
| $1K | – | – | – |
|
28
Barclays
London,
United Kingdom
| $1K | +$1.32K | +134 | New |
|
|
RSCM
29
Rock Springs Capital Management
Baltimore,
Maryland
| – | -$1.68M | -150,000 | Closed |
|
|
OAM
30
Oxford Asset Management
Oxford,
United Kingdom
| – | -$134K | -11,919 | Closed |
|
|
31
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$8K | -700 | Closed |
|
ALPN Hedge Fund Activity: Q1 2018 in Review
28 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q1 2018, worth a combined $63M — down 29% from $88.9M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ALPN positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $334K. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $1.68M sold.
- 28 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q1 2018, up from 27 in Q4 2017.
- Funds reported $63M of Alpine Immune Sciences Inc stock for Q1 2018, down 29% quarter-over-quarter.
- 4 funds opened new Alpine Immune Sciences Inc positions in Q1 2018 and 3 closed out, a net change of +1 holder.
- The largest Alpine Immune Sciences Inc buyer in Q1 2018 was Renaissance Technologies, an estimated $334K added.
- The largest Alpine Immune Sciences Inc seller in Q1 2018 was Rock Springs Capital Management, an estimated $1.68M sold.
Based on aggregated 13F filings for Q1 2018.